Genfit S.A.
GNFT.PA$416M
Small CapEURONEXTBiological Products, (No Diagnostic Substances)🇺🇸North AmericaLOOS188 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
May 15, 2026
8dMarket Overview
Stock performance and key metrics
GNFT.PA News
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
GNS561 + Trametinib Phase 2 Results Expected
May 2026~EstimatedGNS561 + Trametinib74
Primary completion for GNS561 + Trametinib trial (NCT05874414) in Cholangiocarcinoma
SourceDrug Pipeline
GFT505 80mg
Type II Diabetes Mellitus
GNS561 + Trametinib
Cholangiocarcinoma
GFT505 120mg
Non-Alcoholic Steatohepatitis (NASH)
Elafibranor 80 mg
Primary Biliary Cholangitis (PBC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GFT505 80mg | Phase 2 | Type II Diabetes Mellitus | - | - |
GNS561 + Trametinib | Phase 2 | Cholangiocarcinoma | - | - |
GFT505 120mg | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) | - | - |
Elafibranor 80 mg | Phase 2 | Primary Biliary Cholangitis (PBC) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply